Imaging, Patient Demographics May Inform AI Learning in Prostate Cancer


Artificial intelligence may help detect tumors both within the prostate and that have spread to areas outside of the prostate, according to Wayne G. Brisbane, MD.

Future research efforts in the artificial intelligence (AI) space may focus on improving the quality of data that algorithms work with to improve treatment decision making for patients with prostate cancer, according to Wayne G. Brisbane, MD

In a conversation with CancerNetwork® during Prostate Cancer Awareness Month 2023, Brisbane, assistant professor of urology at the University of California, Los Angeles (UCLA) Health, stated that the current quality of data that algorithms are working with creates limitations to implementing AI programs in the clinic. To amend these limitations, he stated that clinical trials may be able to aid machine learning by giving AI data from images, pathology, and patient demographics.

He also raised questions about whether programs such as Unfold AI may be able to predict prostate cancer diagnoses based on imaging and prostate-specific antigen (PSA) levels. Additionally, he described how AI may help monitor whether tumors spread to areas outside the prostate, thereby informing clinicians on certain treatment strategies.


AI is nice in that you can use it anywhere. It can answer many questions, but the limitations are based on the quality of the data that you have for training. I would say that to go forward in the diagnostic space, we are currently trying to create datasets that will help us answer specific questions—for example, can we use imaging and PSA to predict who has prostate cancer?

With Unfold AI, we’re looking at both where the tumor is inside the prostate but also whether the tumor is spreading outside the prostate. That helps us better select who is a good candidate for certain treatments. As the machine learning algorithms continue to improve, we’re also trying now in medicine to think about our data in a way that helps machine learning algorithms improve. A lot of the current clinical trials are capturing images, pathology, and patient demographics in such a way that they will be able to inform machine learning in the next few years.

Related Videos
Cretostimogene grenadenorepvec’s efficacy compares favorably with the current nonsurgical standards of care in high-risk, Bacillus Calmette Guerin–unresponsive non-muscle invasive bladder cancer.
Artificial intelligence models may be “seamlessly incorporated” into clinical workflow in the management of prostate cancer, says Eric Li, MD.
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.
The difference in adverse effect profiles between sorafenib and nirogacestat may make one treatment more appealing than the other for certain patients with desmoid tumors, says Brian Van Tine, MD, PhD.
The Epione robot eliminates the need for multiple check scans during surgery by allowing physicians to target a tumor with a single button press, according to Govindarajan Narayanan, MD.
The Epione robot may help less experienced surgeons carry out complex cases with a high level of accuracy, says Govindarajan Narayanan, MD.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Cell therapy and vaccine approaches are among the several potential options for targeting KRAS in patients with KRAS G12C–mutated non–small cell lung cancer, says Sandip P. Patel, MD.